ASCO Annual Meeting: Lung Cancer | Conference

Phase 2 CITYSCAPE Trial Shows Promise for Tiragolumab in NSCLC
July 04, 2020

Patients with chemotherapy-naïve, locally advanced, or metastatic non-small cell lung cancer who were treated with tiragolumab plus an anti-PD-L1 agent showed better efficacy versus single-agent checkpoint inhibitor therapy alone.

Antibody Drug Conjugate Shows Favorable Clinical Activity in Phase 2 DESTINY-Lung01 Study
July 02, 2020

Fam-trastuzumab deruxtecan-nxki (Enhertu) showed favorable clinical activity with a high objective response rate and durable responses in patients with HER2-mutated non-small cell lung cancer.

Phase 3 KEYNOTE-604 Trial Shows Promise for Pembrolizumab and EP in Patients ES-SCLC
July 01, 2020

The study demonstrated modest survival benefits in patients with extensive-stage small cell lung cancer who received the combination of pembrolizumab and etoposide plus platinum (EP).